Revvity at Morgan Stanley conference: AI, margins and growth

Revvity outlined a 6%-8% long-term organic-growth target, with 2026 operating margins expected in the upper 20s and potential annual margin expansion of roughly 75bps in a normal demand environment. Management cited cash-flow conversion above 90%, raised its second-half life-sciences forecast on stronger instrument and reagent backlog, and expects Signals software—with 106%-107% net retention—to double over four to five years. AI-driven "lab in the loop" workflows are supporting reagent and software demand, while the planned sale of China-focused immunodiagnostics by end-2027 creates a manageable regulatory-timing risk. The company has repurchased about 15% of shares over recent years, reduced leverage, and its shares were up 50% over the past year.

Analysis

RVTY’s upside now depends less on another narrative re-rating and more on converting order commentary into reported organic growth. With the shares near prior highs, the valuation will be sensitive to whether life-science demand broadens beyond a few bulk orders and whether software expansion translates into durable ARR growth rather than modest renewal uplift. The November 13 investor day is the near-term proof point: quantification of Signals revenue, ARR, bookings, AI-linked pipeline, and segment margins would support a higher-quality software/life-science-tools multiple.

The most investable second-order effect is operating leverage. If preclinical budgets recover, RVTY’s reagent and software mix can create earnings growth materially above revenue growth because distribution and account-management costs should not scale proportionally. Conversely, a weak academic/government funding environment has an asymmetric effect: it can delay consumables demand while fixed costs remain, making the margin algorithm more fragile than management’s long-range framing implies. Watch peer commentary from TMO, DHR, A, BRKR and ILMN for independent confirmation of a tools recovery.

The China separation is not an immediate earnings catalyst; it is a 2027 execution overhang with uncertain value realization. A minority stake and commercial rights preserve optionality, but regulatory timing, manufacturing localization, and any deterioration in China diagnostics pricing could reduce proceeds and distract management. The contrarian view is that AI is likely a demand accelerator for experimental throughput, but not yet a separately measurable revenue stream; investors should avoid underwriting a large AI premium before backlog converts and gross-margin mix is disclosed.

Near term, RVTY can outperform if it raises 2027 margin expectations or demonstrates accelerating Signals bookings. Over 6-18 months, the key debate shifts to whether the company can sustain mid-single-digit-plus organic growth through a normalized tools cycle without relying on buybacks to support per-share results.

Key Decisions for Investors

• Initiate a starter long RVTY ahead of the November 13 investor day only on pullbacks; add if management discloses Signals ARR/bookings acceleration and maintains a credible 2027 margin bridge. Target a 10-15% upside over 3-6 months versus 7-9% downside if life-science organic growth fails to improve.
• Use a relative-value expression: long RVTY / short XBI over 6-12 months. RVTY has recurring consumables and diagnostics exposure that should monetize a preclinical spending recovery with less binary clinical-trial risk; exit if biotech funding strengthens but RVTY orders and revenue fail to accelerate.
• Set a confirmation alert for the next earnings release: require reagent backlog conversion, improving reported life-science growth, and no deterioration in gross margin. If any two miss, reduce the long because the AI/validation thesis remains promotional rather than financially validated.
• Do not underwrite value from the China transaction until buyer terms, expected proceeds, transition costs, and regulatory milestones are disclosed. A delay beyond the stated 2027 timing or a downward revision to China-related earnings should be treated as a catalyst to reassess, not average down.